In 2020, the Food and Drug Administration (FDA) approved the first EZH2 inhibitor tazemetostat (EPZ-6438) for the treatment of metastatic or locally advanced epithelioid sarcoma [75]. The gene discussed is EZH2; the disease is epithelioid sarcoma.